Market Research Logo

Allergic Conjunctivitis - Pipeline Review, H2 2015

Allergic Conjunctivitis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Allergic Conjunctivitis - Pipeline Review, H2 2015’, provides an overview of the Allergic Conjunctivitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Allergic Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Conjunctivitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Allergic Conjunctivitis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Allergic Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Allergic Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Allergic Conjunctivitis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Allergic Conjunctivitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Allergic Conjunctivitis Overview
Therapeutics Development
Pipeline Products for Allergic Conjunctivitis - Overview
Allergic Conjunctivitis - Therapeutics under Development by Companies
Allergic Conjunctivitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Allergic Conjunctivitis - Products under Development by Companies
Allergic Conjunctivitis - Companies Involved in Therapeutics Development
Accolade Pharma LLC
Akari Therapeutics, Plc
Aldeyra Therapeutics, Inc.
Allergan Plc
Eleven Biotherapeutics Inc.
Griffin Discoveries BV
NicOx S.A.
Ocular Therapeutix, Inc.
Ohr Pharmaceutical Inc.
Oxagen Limited
Sylentis S.A.
Xencor, Inc.
Allergic Conjunctivitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AGN-229666 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL-53817 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cetirizine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dexamethasone acetate SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs for Allergic Conjunctivitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GD-134 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GD-136 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
isunakinra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KBP-7306 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NS-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OC-2417 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OPX-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize Histamine H1/H4 Receptor for Ophthalmology and Asthma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SYL-116011 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XmAb-7195 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zafi-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allergic Conjunctivitis - Recent Pipeline Updates
Allergic Conjunctivitis - Dormant Projects
Allergic Conjunctivitis - Discontinued Products
Allergic Conjunctivitis - Product Development Milestones
Featured News & Press Releases
Nov 12, 2015: Ora-CAC Model Delivers Successful Phase 3 Data for Ocular Therapeutix's DEXTENZA for Treatment of Allergic Conjunctivitis
Oct 22, 2015: Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis
Oct 15, 2015: Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of Isunakinra (EBI-005) in Patients with Allergic Conjunctivitis
Sep 29, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase IIa Clinical Trial
Aug 12, 2015: Eleven Biotherapeutics Announces First Patients Dosed with EBI-005 in Phase 3 Study in Patients with Moderate to Severe Allergic Conjunctivitis
Jun 16, 2015: Ocular Therapeutix Begins Enrollment in Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis
May 07, 2015: Eleven Biotherapeutics Presents Clinical Data on EBI-005 for the Treatment of Dry Eye Disease and Allergic Conjunctivitis at ARVO 2015 Annual Meeting
Apr 29, 2015: Eleven Biotherapeutics Publishes Clinical Data on EBI-005 for the Treatment of Allergic Conjunctivitis
Apr 22, 2015: Eleven Biotherapeutics Presents Clinical Data on EBI-005 at the ARVO 2015 Annual Meeting
Apr 16, 2015: Eleven Biotherapeutics Presents Phase 2 Clinical Data on EBI-005 for the Treatment of Allergic Conjunctivitis at ASCRS 2015 Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Allergic Conjunctivitis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Allergic Conjunctivitis - Pipeline by Accolade Pharma LLC, H2 2015
Allergic Conjunctivitis - Pipeline by Akari Therapeutics, Plc, H2 2015
Allergic Conjunctivitis - Pipeline by Aldeyra Therapeutics, Inc., H2 2015
Allergic Conjunctivitis - Pipeline by Allergan Plc, H2 2015
Allergic Conjunctivitis - Pipeline by Eleven Biotherapeutics Inc., H2 2015
Allergic Conjunctivitis - Pipeline by Griffin Discoveries BV, H2 2015
Allergic Conjunctivitis - Pipeline by NicOx S.A., H2 2015
Allergic Conjunctivitis - Pipeline by Ocular Therapeutix, Inc., H2 2015
Allergic Conjunctivitis - Pipeline by Ohr Pharmaceutical Inc., H2 2015
Allergic Conjunctivitis - Pipeline by Oxagen Limited, H2 2015
Allergic Conjunctivitis - Pipeline by Sylentis S.A., H2 2015
Allergic Conjunctivitis - Pipeline by Xencor, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Allergic Conjunctivitis Therapeutics - Recent Pipeline Updates, H2 2015
Allergic Conjunctivitis - Dormant Projects, H2 2015
Allergic Conjunctivitis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Allergic Conjunctivitis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Mechanism of Actions, H2 2015
Number of Products by Stage and Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report